All articles tagged with #psoriasis
A dermatologist explains that skin inflammation—especially in psoriasis—can signal systemic inflammation linked to higher heart-disease risk, with psoriasis now listed in American Heart Association guidelines as a risk-enhancing inflammatory condition. Not all inflammatory skin issues carry this risk, but persistent skin changes should prompt medical review for potential links to metabolic syndrome and cardiovascular health.
Takeda's TYK2 inhibitor zasocitinib beat Bristol Myers Squibb's Sotyktu in a Phase 3 head-to-head for moderate-to-severe plaque psoriasis, delivering PASI 100 in over 35% of patients at Week 16 and outperforming on key secondary endpoints with a favorable safety profile; Takeda plans a first-half 2027 launch, signaling continued pressure on Sotyktu as its sales have underperformed since its 2022 approval.
Oruka Therapeutics reports phase 2a results for ORKA-001, a long-acting IL-23 inhibitor for plaque psoriasis, showing 63.5% of treated patients achieving complete skin clearance (40/63) at week 16 versus 1/21 on placebo, with a clean safety profile and potential for annual dosing. Jefferies analysts say the data could outperform Skyrizi and support $5–$10 billion in sales, helping the stock rise about 30% as the company moves to phase 3 with an active comparator.
A new study finds keratin 16 normally suppresses skin inflammation by dampening type I interferon signaling; when KRT16 is mutated or absent, inflammation spikes, linking keratin 16 to conditions like pachyonychia congenita, psoriasis, and eczema. The researchers suggest targeting interferon signaling could yield new treatments, as an interferon inhibitor reduced skin lesions in a mouse PC model.
A 47-year-old woman with plaque psoriasis endures years of failed treatments and emotional distress until she joins a clinical trial for ICOTYDE, the first oral therapy approved for the condition. Her symptoms dramatically clear, transforming both her skin and self-confidence, and she urges others not to let disease define them.
A 47-year-old woman, Amber Dean, suffered years of physical and emotional torment from plaque psoriasis, enduring misdiagnoses and failed treatments until she joined a clinical trial for ICOTYDE, the first oral medication for the condition. She now reports full skin clearance and a renewed sense of self, calling the decision one of her best health choices and urging others not to be defined by the disease.
Johnson & Johnson won U.S. approval for Icotyde, a daily oral medication for moderate-to-severe plaque psoriasis in patients 12 and older, designed to mimic the effects of top-selling injectables like Skyrizi and Tremfya without injections. The pill could expand the patient market and is projected to reach more than $5 billion in peak annual sales, potentially reshaping competition in a multibillion-dollar field.
Researchers found that immune cells formed in inflamed psoriasis skin can migrate into the bloodstream and travel to joints, where they encounter fibroblasts and ignite inflammation leading to psoriatic arthritis. The study explains why only some psoriasis patients develop arthritis and suggests blood-d detectable migratory cells could serve as an early warning, with future therapies aiming to intercept these cells before joint damage occurs.
New research shows that immune cells shed a sugar-rich surface layer called glycocalyx to enter inflamed skin in psoriasis, challenging previous beliefs and opening new avenues for treatment targeting immune cell migration.
A global increase in psoriasis, a chronic inflammatory skin condition, is notably higher in wealthier regions like North America and Western Europe, with cases rising over 86% since 1990. Factors such as better diagnosis, hygiene practices, and immune system responses are believed to contribute, although no cure exists, and management involves topical treatments and light therapy.
New research reveals that immune cells shed their glycocalyx layer to facilitate movement into tissues during inflammation, challenging previous beliefs that only blood vessel walls modify their glycocalyx, which could influence future treatments for inflammatory diseases like psoriasis.
This week in science, a groundbreaking gene therapy for Huntington's disease was announced, a record-breaking tropical storm hit Asia, a black hole exceeded theoretical growth limits challenging current cosmological models, and research linked air pollution to increased psoriasis cases worldwide.
Recent studies reveal a significant link between air pollution and the triggering or worsening of psoriasis, an autoimmune skin condition, with pollutants like PM2.5 and PAHs contributing to inflammation and immune activation. Individuals in polluted environments, such as those near sugarcane burning or factories, are at increased risk, highlighting the need for regulatory action and personal protective measures.
A study suggests that weight loss drugs like Ozempic and Zepbound may provide additional benefits for psoriasis patients, including reduced risks of premature death, heart attacks, strokes, and substance abuse, potentially due to their anti-inflammatory effects and impact on mood and reward systems.
Researchers have found a strong link between central abdominal fat and psoriasis, a chronic inflammatory skin condition, suggesting that body fat distribution plays a crucial role in disease risk and severity. The study highlights the potential of using obesity-related treatments, like GLP-1 receptor agonists, to manage psoriasis, emphasizing the importance of targeted weight management and new therapeutic approaches. The findings underscore the need for clinical trials to explore these drugs as potential psoriasis treatments, especially given the rising obesity rates.